Literature DB >> 19929439

Filamin A regulates monocyte migration through Rho small GTPases during osteoclastogenesis.

Roland Leung1, Yongqiang Wang, Karl Cuddy, Chunxiang Sun, Joyce Magalhaes, Marc Grynpas, Michael Glogauer.   

Abstract

Osteoclastogenesis (OCG) results from the fusion of monocytes after stimulation with macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-kappaB ligand (RANKL). Migration of monocytes into close proximity precedes critical fusion events that are required for osteoclast formation. Cellular migration requires leading-edge actin cytoskeleton assembly that drives cellular locomotion. Filamin A (FLNa) cross-links F-actin filaments in the leading edge of migrating cells and also has been shown to regulate signal transduction during cell migration. However, little is known about the possible role of FLNa in osteoclastogenesis. Our objective in this study was to investigate the role of FLNa in osteoclastogenesis. Bone marrow monocytes isolated from the tibiae and femora of wild type (WT) and Flna-null mice were cultured for 6 days with M-CSF and RANKL, and osteoclasts were identified by tartrate-resistant acid phosphatase (TRACP) staining. The Flna-null mouse skeletal phenotype was characterized using dual-energy X-ray absorptiometry (DXA) to analyze the skeleton, as well as tests on blood chemistry. Osteoclast levels in vivo were quantified by counting of TRACP-stained histologic sections of distal femora. To elucidate the mechanisms by which Flna regulates osteoclastogenesis, migration, actin polymerization, and activation of Rho GTPases, Rac1, Cdc42, and RhoA were assessed in monocytes during in vitro OCG. Deficiencies in migration were rescued using constitutively active Rac1 and Cdc42 TAT fusion proteins. The RANKL signaling pathway was evaluated for activation by monitoring nuclear translocation of NF kappaB and c-jun and expression of key osteoclast genes using quantitative real-time polymerase chain reaction (qRT-PCR). Our results show that Flna-null monocytes formed fewer osteoclasts in vitro, and those that were formed were smaller with fewer nuclei. Decreased OCG was reflected in vivo in TRACP-stained histologic bone sections. Flna-null monocytes experienced impaired migratory ability. When OCG was performed at increasing starting cellular plating densities in order to decrease intercellular distances, there was progressive rescue of Flna-null osteoclast formation comparable with WT levels, confirming that Flna regulates monocyte migration prefusion. Activation of the actin cytoskeleton regulators Rac1, Cdc42, and RhoA and actin free-barbed end generation were partially or completely abrogated in Flna-null monocytes; however, monocyte migration was restored on rescuing with constitutively active Rac1 and Cdc42 TAT fusion proteins. We conclude that filamin A is required for osteoclastogenesis by regulating actin dynamics via Rho GTPases that control monocyte migration. (c) 2010 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19929439     DOI: 10.1359/jbmr.091114

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  32 in total

Review 1.  Modulation of osteoclast differentiation and bone resorption by Rho GTPases.

Authors:  Heiani Touaitahuata; Anne Blangy; Virginie Vives
Journal:  Small GTPases       Date:  2014-03-10

2.  The Cdc42 guanine nucleotide exchange factor FGD6 coordinates cell polarity and endosomal membrane recycling in osteoclasts.

Authors:  Charlotte Steenblock; Tobias Heckel; Cornelia Czupalla; Ana Isabel Espírito Santo; Christian Niehage; Martin Sztacho; Bernard Hoflack
Journal:  J Biol Chem       Date:  2014-05-12       Impact factor: 5.157

3.  Inhibition of osteoclastogenesis by stem cell-derived extracellular matrix through modulation of intracellular reactive oxygen species.

Authors:  Mao Li; Xi Chen; Jinku Yan; Long Zhou; Yifan Wang; Fan He; Jun Lin; Caihong Zhu; Guoqing Pan; Jia Yu; Ming Pei; Huilin Yang; Tao Liu
Journal:  Acta Biomater       Date:  2018-03-08       Impact factor: 8.947

4.  Filamin A expression correlates with proliferation and invasive properties of human metastatic melanoma tumors: implications for survival in patients.

Authors:  Kai Zhang; Tienian Zhu; Dongmei Gao; Yimei Zhang; Qinglan Zhao; Shuang Liu; Tongyi Su; Michel Bernier; Ruijing Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-08       Impact factor: 4.553

5.  Transcriptome-wide landscape of pre-mRNA alternative splicing associated with metastatic colonization.

Authors:  Zhi-xiang Lu; Qin Huang; Juw Won Park; Shihao Shen; Lan Lin; Collin J Tokheim; Michael D Henry; Yi Xing
Journal:  Mol Cancer Res       Date:  2014-10-01       Impact factor: 5.852

6.  Recent advances in understanding the mechanisms of osteoclast precursor fusion.

Authors:  Merry Jo Oursler
Journal:  J Cell Biochem       Date:  2010-08-01       Impact factor: 4.429

7.  Macrophage mesenchymal migration requires podosome stabilization by filamin A.

Authors:  Romain Guiet; Christel Vérollet; Isabelle Lamsoul; Céline Cougoule; Renaud Poincloux; Arnaud Labrousse; David A Calderwood; Michael Glogauer; Pierre G Lutz; Isabelle Maridonneau-Parini
Journal:  J Biol Chem       Date:  2012-02-09       Impact factor: 5.157

8.  Silencing Filamin A Inhibits the Invasion and Migration of Breast Cancer Cells by Up-regulating 14-3-3σ.

Authors:  Zhi-Min Ji; Li-Li Yang; Juan Ni; San-Peng Xu; Cheng Yang; Pei Duan; Li-Ping Lou; Qiu-Rong Ruan
Journal:  Curr Med Sci       Date:  2018-06-22

9.  Rac1 is deactivated at integrin activation sites through an IQGAP1-filamin-A-RacGAP1 pathway.

Authors:  Guillaume Jacquemet; Mark R Morgan; Adam Byron; Jonathan D Humphries; Colin K Choi; Christopher S Chen; Patrick T Caswell; Martin J Humphries
Journal:  J Cell Sci       Date:  2013-07-10       Impact factor: 5.285

Review 10.  Filamin A Regulates Cardiovascular Remodeling.

Authors:  Sashidar Bandaru; Chandu Ala; Alex-Xianghua Zhou; Levent M Akyürek
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.